These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38498261)

  • 1. Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
    Bobholz SA; Hoefs A; Hamburger J; Lowman AK; Winiarz A; Duenweg SR; Kyereme F; Connelly J; Coss D; Krucoff M; Banerjee A; LaViolette PS
    J Neurooncol; 2024 Apr; 167(2):243. PubMed ID: 38498261
    [No Abstract]   [Full Text] [Related]  

  • 2. Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
    Bobholz SA; Hoefs A; Hamburger J; Lowman AK; Winiarz A; Duenweg SR; Kyereme F; Connelly J; Coss D; Krucoff M; Banerjee A; LaViolette PS
    J Neurooncol; 2024 Apr; 167(2):233-241. PubMed ID: 38372901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response.
    Bobholz SA; Hoefs A; Hamburger J; Lowman AK; Winiarz A; Duenweg SR; Kyereme F; Connelly J; Coss D; Krucoff M; Banerjee A; LaViolette PS
    Res Sq; 2024 Jan; ():. PubMed ID: 38260400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radio-Pathomic Maps of Cell Density Identify Brain Tumor Invasion beyond Traditional MRI-Defined Margins.
    Bobholz SA; Lowman AK; Brehler M; Kyereme F; Duenweg SR; Sherman J; McGarry SD; Cochran EJ; Connelly J; Mueller WM; Agarwal M; Banerjee A; LaViolette PS
    AJNR Am J Neuroradiol; 2022 May; 43(5):682-688. PubMed ID: 35422419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival.
    Hattingen E; Jurcoane A; Daneshvar K; Pilatus U; Mittelbronn M; Steinbach JP; Bähr O
    Neuro Oncol; 2013 Oct; 15(10):1395-404. PubMed ID: 23925453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI.
    Lescher S; Jurcoane A; Veit A; Bähr O; Deichmann R; Hattingen E
    Neuroradiology; 2015 Jan; 57(1):11-20. PubMed ID: 25287076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.
    Ellingson BM; Kim HJ; Woodworth DC; Pope WB; Cloughesy JN; Harris RJ; Lai A; Nghiemphu PL; Cloughesy TF
    Radiology; 2014 Apr; 271(1):200-10. PubMed ID: 24475840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrast enhancing pattern on pre-treatment MRI predicts response to anti-angiogenic treatment in recurrent glioblastoma: comparison of bevacizumab and temozolomide treatment.
    Moon HH; Park JE; Kim YH; Kim JH; Kim HS
    J Neurooncol; 2022 May; 157(3):405-415. PubMed ID: 35275335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
    Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
    Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab.
    Leu K; Enzmann DR; Woodworth DC; Harris RJ; Tran AN; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
    Cancer Imaging; 2014 Nov; 14(1):31. PubMed ID: 25608485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas.
    Kim BS; Kim SK; Choi SH; Lee SH; Seol HJ; Nam DH; Lee JI; Park CK; Kong DS
    J Neurooncol; 2015 Aug; 124(1):101-10. PubMed ID: 26026859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
    Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
    J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
    Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
    Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early assessment of recurrent glioblastoma response to bevacizumab treatment by diffusional kurtosis imaging: a preliminary report.
    Lee CY; Kalra A; Spampinato MV; Tabesh A; Jensen JH; Helpern JA; de Fatima Falangola M; Van Horn MH; Giglio P
    Neuroradiol J; 2019 Oct; 32(5):317-327. PubMed ID: 31282311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
    Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
    Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI and
    Wirsching HG; Roelcke U; Weller J; Hundsberger T; Hottinger AF; von Moos R; Caparrotti F; Conen K; Remonda L; Roth P; Ochsenbein A; Tabatabai G; Weller M
    Clin Cancer Res; 2021 Jan; 27(1):179-188. PubMed ID: 32967939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
    Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
    Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.
    Yao J; Tan CHP; Schlossman J; Chakhoyan A; Raymond C; Pope WB; Salamon N; Lai A; Ji M; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2019 May; 142(3):587-595. PubMed ID: 30806888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
    Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
    Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
    Narita Y
    Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.